ABOUT EVENT
Attention
Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.
What Can You Expect at the Novel Combination Cancer Immunotherapy Summit?
With 3 days jam-packed with data-driven case studies and engaging discussions, the Novel Combination Cancer Immunotherapy Summit 2024 would accelerate your preclinical pipelines towards robust clinical candidates with higher rate of success and benefit for patients in need.
Key Headings
How to develop rational combination strategies of novel immunotherapies, including adoptive cell therapies, ADCs and antibodies, oncolytic therapies, ICIs and cytokine therapy.
How to identify and validate biomarkers, select optimal preclinical models and interpret preclinical data to predict patient response and tumor resistance.
How to design smart clinical trials for combination strategies which consider patient safety, therapeutic potency and regulatory approval.
How to forge strategic collaborations and successfully manage stakeholders with economical, commercial and market access considerations at the forefront of mind.
With expert speakers with proficiency across immunotherapy from pioneering companies this meeting will focus on innovative modalities and rational combination strategies which enhance efficacy, reduce toxicity and improve patient outcome.
Agenda Snapshots
Optimal Combination Selection using Biomarkers - Ensure the best selection of immune therapies through leveraging biomarkers towards enhancing combo efficacy and minimizing off-target effects with insights from Lokon Pharma AB.
Exhibiting Latest Breakthrough Data & Clinical Case Studies: Utilizing data and clinical case studies provides valuable insights into the effectiveness of different immune therapy combinations, helping clinicians make informed decisions based on real-world evidence with insights from Amgen.
Optimizing the Delivery of Combination Therapies: Understanding how to best deliver combination therapies ensures maximum therapeutic benefit while minimizing toxicity, ultimately improving patient tolerance and treatment outcomes in immune therapy with insights from Ankyra Therapeutics & Candel Therapeutics.
How to Leverage High-Value Combinations to Overcome Resistance & Tumor Heterogeneity: Addressing resistance and tumor heterogeneity towards improved patient outcomes through targeting of various mechanisms of immune evasion and tumor adaptation with insights from Oncolys & TVAX Biomedical